Analyst Price Target is $12.00
▲ +118.78% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Zevra Therapeutics in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 118.78% upside from the last price of $5.49.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in Zevra Therapeutics.
Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.